Small molecule · Agonist of glucocorticoid receptor (NR3C1) · developed by Ptc Therap
Deflazacort is a corticosteroid prodrug whose active metabolite, 21-desDFZ, acts through the glucocorticoid receptor to produce anti-inflammatory and immunosuppressive effects. It is studied in limb-girdle muscular dystrophy.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT03783923 | Phase 3 | Limb-Girdle Muscular Dystrophy | Terminated | PTCT |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Limb-Girdle Muscular Dystrophy
Updated Oct 25, 2026. Something wrong or missing? Report it on the PTCT page.
See PTCT's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
PTCT catalysts and pipeline →